Clinical Summary:

• Design/Population: The phase 3 FrontMIND trial randomized previously untreated patients with high-risk aggressive B-cell lymphomas, including diffuse large B-cell lymphoma and high-grade B-cell lymphoma, to receive either tafasitamab plus lenalidomide and R-CHOP or R-CHOP alone.
• Key Outcomes: Tafasitamab plus lenalidomide and R-CHOP reduced the risk of progression by 25% and improved 2-year progression-free survival by 8.2% compared with R-CHOP alone. Molecular remission rates were higher with the investigational regimen (81% vs 67%), while event-free survival also significantly improved.
• Clinical Relevance: These findings support tafasitamab plus lenalidomide and R-CHOP as a potential new frontline treatment option for patients with high-risk aggressive B-cell lymphomas.

Georg Lenz, MD, University Hospital Münster and German Lymphoma Alliance, Münster, Germany, discusses results from the phase 3 FrontMIND trial evaluating the addition of tafasitamab and lenalidomide to R-CHOP in patients with previously untreated high-risk aggressive B-cell lymphomas. The study enrolled a particularly high-risk population characterized by elevated IPI scores, elevated LDH levels, and rapid treatment initiation following diagnosis.

The addition of tafasitamab and lenalidomide significantly improved progression-free survival (PFS) and event-free survival (EFS) while producing deeper molecular responses compared with standard R-CHOP. Although treatment-related toxicities, including hematologic adverse events and infections, were more common, the safety profile was considered manageable, supporting the regimen as a promising new option for frontline treatment of high-risk aggressive lymphoma.

Dr Lenz presented these results at the 2026 EHA Congress in Stockholm, Sweden.

Transcript: 

Hello everybody. My name is Georg Lenz, I’m the director of the department of hematology and oncology at the University Hospital Münster and also chair of the German Lymphoma Alliance, which is the German study group on lymphoma.

Today I would like to summarize the FrontMIND study, and I had the privilege of presenting these results in the plenary session of the EHA meeting in Stockholm. 

The FrontMIND study was a randomized, international phase 3 trial that investigated the efficacy and safety of tafasitamab plus lenalidomide and R-CHOP versus R-CHOP alone in previously untreated patients with aggressive lymphoma and an intermediate- or high-risk profile. Patients included in the study had diffuse large B-cell lymphoma, including different subtypes, as well as high-grade B-cell lymphomas. These patients were characterized by an IPI score of 3 to 5 or an age-adjusted IPI of 2 to 3. In addition, the interval between diagnosis and initiation of therapy had to be 28 days or less. 

As a result, we treated a truly high-risk population. For example, 80% of patients had elevated LDH levels, and an IPI score of 4 to 5 was present in more than 40% of patients. The primary end point was progression-free survival. Key secondary endpoints included overall survival, event-free survival, and, of course, safety. In total, 889 patients were randomized: 448 patients to the tafasitamab, lenalidomide, and R-CHOP arm, and 451 patients to the R-CHOP arm.

Coming to the results, the combination of the anti-CD19 antibody tafasitamab plus lenalidomide and R-CHOP significantly improved progression-free survival compared with R-CHOP alone. This translated into a 25% reduction in the risk of progression or death. Numerically, there was an 8.2% difference in progression-free survival after 2 years. To me, this is obviously a clearly positive study because the primary end point was met. But it is also clinically meaningful because I think an 8.2% progression-free survival advantage is very important for patients. 

Looking at the secondary end points, event-free survival was also significantly better in patients treated with tafasitamab plus lenalidomide and R-CHOP. When we look at overall survival, this is still an interim analysis, and we will reassess overall survival in approximately two years. However, there was already a trend toward improved overall survival in the tafasitamab arm. After 2 years, 84% of patients treated with tafasitamab plus R-CHOP were alive compared with 80% of patients treated with R-CHOP alone.

Interestingly, response rates were not dramatically different. The rate of metabolic complete remission was roughly 65% in both groups. There was a slightly higher rate of partial remission, about 4% higher, in the tafasitamab arm compared with R-CHOP alone. However, when we looked at molecular remissions, MRD negativity was achieved in 81% of patients treated with tafasitamab plus R-CHOP compared with 67% in the R-CHOP arm. This suggests that tafasitamab plus R-CHOP induces deeper remissions than R-CHOP alone.

Looking at safety, overall, tafasitamab plus R-CHOP was more toxic than R-CHOP alone. This was true for higher-grade treatment-emergent adverse events, and fatal adverse events were also more frequent. However, it is important to remember that the study was conducted during the COVID-19 pandemic. A major contributor to the higher death rate was COVID-19–related mortality. In addition, sepsis and pneumonia occurred more frequently in patients treated with tafasitamab plus R-CHOP.

When we looked at hematologic toxicities, these were also more frequent in the tafasitamab arm, which led to a higher rate of neutropenic fever. This is likely attributable to the addition of lenalidomide. Overall, the addition of tafasitamab and lenalidomide to R-CHOP led to more toxicity, but these toxicities were manageable.

To summarize, this is clearly a positive trial. If this regimen is approved and reimbursed, I believe it will represent a new treatment option for patients with high-risk aggressive lymphoma. These results are particularly exciting because this is only the second positive frontline phase III trial in this disease setting. The other was the POLARIX trial, which introduced pola-R-CHP into the treatment landscape.

Going forward, we will need to understand which patients are better suited for one approach versus the other. Obviously, these studies were not directly compared, so we cannot draw conclusions between them. However, I do believe that if tafasitamab plus lenalidomide and R-CHOP becomes available in the future, our patients will benefit from its introduction. With that, I would like to conclude. Thank you very much.

Source:

Lenz G, Trneny M, Burke JM, et al. Tafisitamab Plus Lenalidomide and R-CHOP for patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results form the phase 3 FRONTMIND study. Presented at EHA Congress. June 11 - June 14, 2026. Stockholm, Sweden. Abstract EHA-2190.